OPEN ACCESS Freely available online

Journal of Clinical & Experimental Cardiology

Commentary

Prevalence of Silent Myocardial Ischemia in Patients with Type 2 Diabetes Mellitus

Karim Volkov*

Department of Clinical Medicine, Eastbridge University, Warsaw, Poland

DESCRIPTION

Type 2 diabetes mellitus is a chronic metabolic disorder that affects millions of individuals worldwide and is recognized as a major contributor to cardiovascular disease. Among the various cardiovascular complications associated with diabetes, silent myocardial ischemia represents a particularly important clinical condition due to its asymptomatic nature. Silent myocardial ischemia refers to a reduction in blood supply to the heart muscle that occurs without the typical symptoms of chest pain or discomfort. Because patients often remain unaware of the condition, diagnosis may be delayed until serious cardiac complications develop.

The prevalence of silent myocardial ischemia in patients with type 2 diabetes mellitus has been investigated extensively over the past several decades. Findings from numerous clinical studies indicate that diabetic patients are significantly more likely to experience asymptomatic ischemic episodes compared with individuals without diabetes. This increased occurrence is associated with multiple metabolic, vascular, and neurological abnormalities that accompany long-standing diabetes. As a result, silent myocardial ischemia has become an important area of interest in cardiovascular medicine and diabetes care.

Several mechanisms contribute to the development of silent myocardial ischemia among diabetic individuals. One of the most commonly recognized factors is diabetic autonomic neuropathy. Chronic elevations in blood glucose can damage autonomic nerve fibers responsible for transmitting pain signals from the heart. Consequently, ischemic episodes that would ordinarily produce chest pain may occur without any noticeable symptoms. This diminished pain perception can allow significant coronary artery disease to progress undetected over extended periods.

Coronary atherosclerosis also plays a major role in the occurrence of silent ischemia. Patients with type 2 diabetes frequently develop accelerated atherosclerotic changes within coronary arteries. Elevated blood glucose levels contribute to endothelial dysfunction, vascular inflammation, lipid abnormalities, and structural changes within blood vessels. These alterations reduce coronary blood flow and increase the likelihood of myocardial oxygen supply-demand imbalance. When combined with impaired pain perception, these vascular changes create conditions favorable for silent ischemic episodes. Obesity and physical inactivity further influence prevalence rates. Excess body weight is associated with insulin resistance, inflammation, hypertension, and lipid abnormalities. These factors collectively increase cardiovascular risk and may contribute to the development of coronary artery disease. Regular physical activity, in contrast, supports cardiovascular health through improvements in blood pressure, glucose metabolism, and endothelial function.

Detection of silent myocardial ischemia presents a significant clinical challenge because patients do not report characteristic symptoms. Healthcare providers must therefore rely on diagnostic testing to identify affected individuals. Resting electrocardiography may reveal evidence of previous ischemic injury, although normal findings do not exclude the presence of disease. Exercise stress testing remains one of the most frequently utilized methods for identifying inducible ischemia in asymptomatic patients. Additional diagnostic approaches include stress echocardiography, myocardial perfusion imaging, and coronary computed tomography.

Myocardial perfusion imaging has demonstrated value in identifying areas of reduced blood flow within the heart. This technique can detect ischemic abnormalities even when patients remain symptom-free. Similarly, stress echocardiography allows evaluation of cardiac wall motion during exercise or pharmacological stress, helping clinicians identify regions affected by inadequate perfusion. Advances in imaging technology have improved diagnostic accuracy and enhanced the ability to identify individuals at elevated cardiovascular risk. Microvascular complications of diabetes may also be associated with silent myocardial ischemia. Patients with diabetic retinopathy, nephropathy, or peripheral neuropathy often exhibit a greater prevalence of cardiovascular disease. These complications reflect widespread vascular injury that affects multiple organ systems. The presence of microvascular disease

Correspondence to: Karim Volkov, Department of Clinical Medicine, Eastbridge University, Warsaw, Poland, E-mail: karim.volkov.research@globalmedjournal.org

Received: 02-Mar-2026, Manuscript No. JCEC-26-42411; **Editor assigned:** 04-Mar-2026, PreQC No. JCEC-26-42411 (PQ); **Reviewed:** 18-Mar-2026, QC No. JCEC-26-42411; **Revised:** 25-Mar-2026, Manuscript No. JCEC-26-42411 (R); **Published:** 01-Apr-2026, DOI: 10.35248/2155-9880.26.17.1004

Citation: Volkov K (2026). Prevalence of Silent Myocardial Ischemia in Patients with Type 2 Diabetes Mellitus. J Clin Exp Cardiolog. 17:1004.

may therefore serve as an indicator of increased likelihood for silent coronary abnormalities.

The clinical significance of silent myocardial ischemia extends beyond its prevalence. Numerous studies have demonstrated that affected individuals face increased risks of myocardial infarction, heart failure, arrhythmias, and cardiovascular mortality. Since ischemic episodes may occur repeatedly without recognition, cumulative myocardial damage can develop over time. Delayed diagnosis may limit opportunities for early intervention and increase the probability of adverse outcomes.

Management strategies focus on reducing cardiovascular risk and preventing disease progression. Optimal glycemic control remains an important component of care. Blood pressure management, lipid reduction, smoking cessation, weight control, and regular physical activity contribute to overall cardiovascular protection. Pharmacological therapies, including antiplatelet agents, statins, antihypertensive medications, and glucose-lowering drugs, may be incorporated according to individual patient characteristics and clinical recommendations.

The growing global burden of type 2 diabetes highlights the importance of recognizing silent myocardial ischemia as a significant cardiovascular concern. Increasing awareness among healthcare professionals and patients may encourage earlier identification of risk factors and support preventive interventions. Routine clinical assessments that include cardiovascular risk evaluation can contribute to improved patient outcomes and reduced disease burden.

CONCLUSION

The prevalence of silent myocardial ischemia in patients with type 2 diabetes mellitus remains substantial and represents an important challenge in contemporary clinical practice. The condition is influenced by autonomic neuropathy, coronary artery disease, poor glycemic control, hypertension, dyslipidemia, obesity, and other cardiovascular risk factors. Because symptoms are absent, diagnosis frequently requires specialized testing. Early recognition and comprehensive risk-factor management may reduce cardiovascular complications and improve long-term outcomes among individuals living with type 2 diabetes mellitus.